CARB 4 |
| Nucleosides, a very mature class of drugs, provide front-line therapy for many viral infections and cancer, but new drug discoveries are constrained by multiple limitations and, may have little left to offer. Nucleoside Monophosphate Prodrugs, although receiving considerable research has yet to generally overcome typical nucleoside pharmacokinetic deficiencies. Acyclic Nucleoside Phosphonates, ANPs, e.g. phosphonylmethoxyalkyl mimics of nucleoside monophosphates, a relatively mature class of drugs, has not progressed beyond HIV/HBV applications. Antisense Oligonucleotides, including the newer siRNA oligonucleotides, despite enthusiastically received promise, face challenging development obstacles and have yet to fulfill expectations. Nucleoside Phosphate Mimics (NPMs), a hybrid of heterocycles, nucleosides, and subunits of oligonucleotides, represents an exciting, novel class of potential drugs that may overcome deficiencies of nucleosides, ANPs and oligonucleotides. In this presentation, I will discuss select lead discoveries in these classes of Nucleic Acids Materials, with an emphasis on collaborative work with Muthiah Manoharan, the 2007 Wolfrom Award Recipient. |
|
Wolfrom/Isbell/New Investigator Award Symposium
8:30 AM-11:50 AM, Sunday, August 19, 2007 BCEC -- 162B, Oral
Division of Carbohydrate Chemistry |